Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Dicumarol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VKORC1 known ✓ | Q9BQB6 | 8/20 | 0.72 |
| ▸ | NQO1 | P15559 | 6/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | TP53 | P04637 | 2/20 | 1.00 |
| ▸ | TSHR | P16473 | 2/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | PDE4D | Q08499 | 1/20 | 1.00 |
| ▸ | PCSK7 | Q16549 | 1/20 | 1.00 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dicumarol SCHEMBL33891 | 1.00 | NQO1 (1.00) | NQO1ALDH1A1LMNATP53TSHR | |
| Dicumarol SCHEMBL7454901 | 1.00 | NQO1 (1.00) | NQO1ALDH1A1LMNATP53TSHR | |
| Dicumarol SCHEMBL17927706 | 0.98 | NQO1 (0.96) | NQO1ALDH1A1LMNATP53TSHR | |
| SCHEMBL1648186 | 0.90 | NQO1 (1.00) | NQO1ALDH1A1LMNATP53TSHR | |
| SCHEMBL7406496 | 0.87 | NQO1 (0.77) | NQO1ALDH1A1LMNATP53TSHR | |
| SCHEMBL1648127 | 0.87 | NQO1 (0.83) | NQO1ALDH1A1LMNATP53TSHR | |
| SCHEMBL3175636 | 0.86 | NQO1 (0.81) | NQO1ALDH1A1LMNATP53TSHR | |
| SCHEMBL6589409 | 0.86 | NQO1 (0.75) | NQO1ALDH1A1LMNATP53TSHR | |
| SCHEMBL9526995 | 0.86 | NQO1 (0.75) | NQO1ALDH1A1LMNATP53TSHR | |
| SCHEMBL14169915 | 0.86 | NQO1 (0.75) | NQO1ALDH1A1LMNATP53TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2802871-B1 | CHARACTERIZATION OF SUBVISIBLE PARTICLES USING A PARTICLE ANALYZER | TAKEDA PHARMACEUTICALS CO (JP) | 2022-07-27 | — | — | EP | claimed |
| US-20260144871-A1 | Human Placental Derived Natural Killer Cells with High Affinity and Cleavage Resistant CD16 and Secreted IL-15, and uses thereof | CELULARITY INC. (US) | 2026-05-28 | — | — | US | disclosed |
| US-20260136146-A1 | AUDIO DEVICE AND PORTABLE DEVICE | ALPS ALPINE CO LTD (JP) | 2026-05-14 | — | — | US | disclosed |
| EP-4742701-A1 | AUDIO DEVICE AND PORTABLE DEVICE | Alps Alpine Co., Ltd. (JP) | 2026-05-13 | — | — | EP | disclosed |
| CN-122027971-A | Audio device and portable apparatus | 阿尔卑斯阿尔派株式会社 | 2026-05-12 | — | — | CN | disclosed |
| US-12610730-B2 | Metal complex and light emitting device | CITY UNIVERSITY OF HONG KONG (HK) | 2026-04-21 | — | — | US | disclosed |
| US-20250113821-A1 | Methods and Compositions for Preserving Tissues and Organs | MASSACHUSETTS GEN HOSPITAL (US) | 2025-04-10 | — | — | US | disclosed |
| CN-119344773-B | Method and system for quantitatively grading musculoskeletal ultrasonic ultramicro blood flow based on optical flow analysis | 浙江大学 | 2025-03-21 | — | — | CN | disclosed |
| CN-119344773-A | Method and system for quantitatively grading musculoskeletal ultrasonic ultramicro blood flow based on optical flow analysis | 浙江大学 | 2025-01-24 | — | — | CN | disclosed |
| EP-4486913-A1 | METHODS, COMPOSITIONS, AND KITS FOR MULTIPLE BARCODING AND/OR HIGH-DENSITY SPATIAL BARCODING | 10x Genomics, Inc. (US) | 2025-01-08 | — | — | EP | disclosed |
| WO-2023250077-A1 | METHODS, COMPOSITIONS, AND SYSTEMS FOR CAPTURING PROBES AND/OR BARCODES | 10X GENOMICS, INC. (US) | 2023-12-28 | — | — | WO | disclosed |
| CN-116973465-A | Method for improving sensitivity of liquid chromatography-mass spectrometry for detecting vitamin K1 in serum | 翊新诊断技术(苏州)有限公司 | 2023-10-31 | — | — | CN | disclosed |
| WO-2023137344-A1 | CLEAVAGE RESISTANT CD16 CONSTRUCTS AND USES THEREOF | CELULARITY INC. (US) | 2023-07-20 | — | — | WO | disclosed |
| US-20230006152-A1 | METAL COMPLEX AND LIGHT EMITTING DEVICE | CITY UNIVERSITY OF HONG KONG (HK) | 2023-01-05 | — | — | US | disclosed |
| EP-4076411-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR PREVENTION AND/OR TREATMENT OF DYSBIOSIS AND ANTIBACTERIAL ANTIDOTES FOR MICROBIOME-PROTECTION | European Molecular Biology Laboratory (DE) | 2022-10-26 | — | — | EP | disclosed |
| CN-112043835-B | Bioreversible introducing group for nitrogen and hydroxyl-containing drugs | 韩捷 | 2022-10-21 | — | — | CN | disclosed |
| WO-2022192372-A1 | METHODS AND COMPOSITIONS FOR TUSC2 COMBINATION THERAPY WITH PDK1 INHIBITION | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-09-15 | — | — | WO | disclosed |
| EP-4041311-A1 | METHODS AND SYSTEMS USING PEPTIDES FOR TARGETING AND MAPPING HUMAN NERVES IN IMAGE GUIDED SURGERY, DIAGNOSTICS AND THERAPEUTIC DELIVERY | Alume Biosciences, Inc. (US) | 2022-08-17 | — | — | EP | disclosed |
| WO-2022120177-A1 | NERVE TARGETING PEPTIDES AND METHODS OF USE | ALUME BIOSCIENCES, INC. (US) | 2022-06-09 | — | — | WO | disclosed |
| CN-109207512-B | Plant regulatory elements and uses thereof | 孟山都技术公司 | 2022-06-03 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230006152-A1 | METAL COMPLEX AND LIGHT EMITTING DEVICE | OCIAD1, OCIAD2, OPRD1 | VKORC1 725/4885NQO1 256/4885ALDH1A1 1905/4885 |
| US-12610730-B2 | Metal complex and light emitting device | OPRD1, OCIAD2, ORC3 | VKORC1 1472/4885NQO1 1984/4885ALDH1A1 4413/4885 |
| US-20260144871-A1 | Human Placental Derived Natural Killer Cells with High Affinity and Cleavage Resistant CD16 and Secreted IL-15, and uses thereof | IL15RA, IL15, PBK | VKORC1 4491/4885NQO1 4264/4885ALDH1A1 4343/4885 |
| US-20260136146-A1 | AUDIO DEVICE AND PORTABLE DEVICE | PURB, RPRD2, PUM2 | VKORC1 4405/4885NQO1 4480/4885ALDH1A1 3896/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.